BCL2L11 and non-small cell lung carcinoma: Finally, 20 datasets from 18 studies [18–23, 35–46] exploring the association between BIM deletion polymorphism and EGFR-TKI efficacy in EGFR-mutant NSCLC patients were included in our meta-analysis (Figure 1).